You are here

  • Home
  • Archive
  • Volume 65, Issue 9
  • Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study

Citation Tools

Article menu

Download PDFPDF

XML
Helicobacter pylori
Original article
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Murakami K, Sakurai Y, Shiino M, et al
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Gut 2016;65:1439-1446.